Immix Biopharma announced that enrollment in its NEXICART‑2 Phase 2 study of the NXC‑201 CAR‑T therapy for relapsed/refractory AL amyloidosis has been completed. The 40‑patient trial, which began in 2025, reached its enrollment target on the day of the announcement, removing a major regulatory hurdle and allowing the company to move forward with accelerated review under its RMAT and orphan drug designations.
The completion of enrollment positions NXC‑201 for a rapid regulatory pathway. The therapy has already received Breakthrough Therapy Designation, and the RMAT status is intended to expedite the review process for treatments that address serious conditions with unmet needs. With enrollment closed, Immix can now focus on collecting the final data needed for a Biologics License Application (BLA) and a planned commercial launch following the expected topline release in the third quarter of 2026.
"In AL Amyloidosis, the immune system produces toxic light chains that clog up the heart, kidney and liver, causing organ failure and death. In our trials, we have seen that one‑and‑done NXC‑201 eliminates the source of these toxic light chains. If approved, NXC‑201 would be the first FDA approved treatment for relapsed/refractory AL Amyloidosis," said CEO Ilya Rachman. CFO Gabriel Morris added, "We are grateful to patients, families, caregivers, investigators, and credit our team's tireless efforts. Building on our positive interim readout at ASH 2025, topline NEXICART‑2 results are expected in Q3, driving BLA submission and planned commercial launch."
Immix also announced the appointment of Richard Graydon as Chief Medical Officer. Graydon brings experience as a senior executive at Merck and Johnson & Johnson and will lead the BLA preparation, underscoring the company’s intent to accelerate the regulatory and commercialization process.
NXC‑201 is a BCMA‑targeted CAR‑T therapy that incorporates a digital filter to reduce non‑specific activation, and early data have shown no neurotoxicity in AL amyloidosis patients. The therapy addresses a serious unmet need: there are no FDA‑approved treatments for relapsed/refractory AL amyloidosis, and the U.S. patient population is estimated at 38,500 in 2026. The amyloidosis market is projected to grow from $3.6 billion in 2017 to $6 billion by 2025, making a first‑in‑class therapy a potentially significant commercial opportunity.
Immix’s market cap was $432 million as of March 30 2026, and the company has delivered a 380 % return over the past year. The company’s recent milestones—including a positive interim readout at ASH 2025 and the Breakthrough Therapy designation—have attracted analyst coverage from Citizens, H.C. Wainwright, and Mizuho, all of whom have maintained positive outlooks on the company’s pipeline and commercial prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.